Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Everest Medicines Ltd.
Headquarters: Shanghai, China
Website: http://www.everestmedicines.c...
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Yong Qing Luo, MD, EMBA
Number Of Employees: 665
Enterprise Value: $1,859,592,753
PE Ratio: -16.68
Exchange/Ticker 1: HKEX:1952
Exchange/Ticker 2: N/A
Latest Market Cap: $2,437,465,068
BioCentury | May 28, 2024
Deals
Asahi Kasei rides renal momentum with $1.1B Calliditas takeout
Deal gives Japanese pharma Tarpeyo, first drug approved to treat IgA nephropathy
BioCentury | Mar 19, 2024
Management Tracks
Syndax names new commercial head
Plus: Everest hires Sandra Zeng as CMO and Rico Liang as chief product officer, and updates from Parexel, Dignify and GRO
BioCentury | Dec 5, 2023
Product Development
Dec. 4 Quick Takes: EyePoint’s data for Eylea competitor drive big gain
Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech
BioCentury | Sep 22, 2023
Deals
Sept. 21 Quick Takes: Catalys-backed newco buys regional rights to Inventiva NASH therapy
Plus: Everest takes local rights to Kezar’s lupus nephritis treatment, and updates from Celexor, GSK, Jura, Syena, Moucellion and Xungene
BioCentury | Jun 16, 2023
Management Tracks
Arvinas’ Houston appointed chairperson
Plus: Berry joins Everest and updates from Avita and Vivoryon
BioCentury | Mar 17, 2023
Product Development
March 16 Quick Takes: Merck latest to report disappointing TIGIT data
Plus: FDA panel reversal for DMD gene therapy sinks Sarepta shares and updates from Esperion, Everest and more
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Aug 26, 2022
Management Tracks
Leading China biotechs Everest, CStone announce CEO departures
Plus updates from BD, Sema4,
BioCentury | Aug 17, 2022
Regulation
Aug. 16 Quick Takes: Everest extends runway by offloading Trodelvy
Plus Flagship’s Senda raises $123M and updates from Bluejay, AZ, Ventyx and more
Items per page:
1 - 10 of 71